NasdaqGM - Delayed Quote USD

Applied Therapeutics, Inc. (APLT)

4.6700 +0.1700 (+3.78%)
At close: 4:00 PM EDT
4.9500 +0.28 (+6.00%)
After hours: 7:17 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
-477.0000
9,993.0000
--
--
--
--
Operating Expense
74,293.0000
74,528.0000
82,950.0000
105,618.0000
94,466.0000
--
Operating Income
-74,770.0000
-64,535.0000
-82,950.0000
-105,618.0000
-94,466.0000
--
Net Non Operating Interest Income Expense
1,737.0000
1,372.0000
685.0000
555.0000
559.0000
--
Other Income Expense
-120,531.0000
-56,600.0000
-243.0000
-521.0000
-54.0000
--
Pretax Income
-193,564.0000
-119,763.0000
-82,508.0000
-105,584.0000
-93,961.0000
--
Net Income Common Stockholders
-193,564.0000
-119,763.0000
-82,508.0000
-105,584.0000
-93,961.0000
--
Diluted NI Available to Com Stockholders
-193,564.0000
-119,763.0000
-82,508.0000
-105,584.0000
-93,961.0000
--
Basic EPS
-1.91
--
-2.18
-4.12
-4.28
-3.55
Diluted EPS
-1.91
--
-2.18
-4.12
-4.28
-3.55
Basic Average Shares
101,484.7460
--
37,825.4310
25,598.1810
21,966.3260
12,831.2210
Diluted Average Shares
101,484.7460
--
37,825.4310
25,598.1810
21,966.3260
12,831.2210
Total Operating Income as Reported
-74,770.0000
-64,535.0000
-82,950.0000
-105,618.0000
-94,466.0000
--
Total Expenses
74,293.0000
74,528.0000
82,950.0000
105,618.0000
94,466.0000
--
Net Income from Continuing & Discontinued Operation
-193,564.0000
-119,763.0000
-82,508.0000
-105,584.0000
-93,961.0000
--
Normalized Income
-73,117.0000
-63,190.0000
-82,442.0000
-105,584.0000
-93,961.0000
--
Interest Income
1,737.0000
1,372.0000
685.0000
--
--
--
Net Interest Income
1,737.0000
1,372.0000
685.0000
555.0000
559.0000
--
EBIT
-74,770.0000
-64,535.0000
-82,950.0000
-105,618.0000
-94,466.0000
--
EBITDA
-74,410.0000
-64,181.0000
-82,507.0000
-105,203.0000
-94,086.0000
--
Reconciled Depreciation
360.0000
354.0000
443.0000
415.0000
380.0000
--
Net Income from Continuing Operation Net Minority Interest
-193,564.0000
-119,763.0000
-82,508.0000
-105,584.0000
-93,961.0000
--
Total Unusual Items Excluding Goodwill
-120,447.0000
-56,573.0000
-66.0000
--
--
--
Total Unusual Items
-120,447.0000
-56,573.0000
-66.0000
--
--
--
Normalized EBITDA
46,037.0000
-7,608.0000
-82,441.0000
-105,203.0000
-94,086.0000
--
12/31/2019 - 5/14/2019

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

EPIX ESSA Pharma Inc.
5.72
-1.72%
 
PHAT Phathom Pharmaceuticals, Inc.
10.60
+9.50%
 
SNDX Syndax Pharmaceuticals, Inc.
19.50
+0.52%
 
CUE Cue Biopharma, Inc.
1.4800
-8.64%
 
KZR Kezar Life Sciences, Inc.
0.6847
+1.44%
 
ATRA Atara Biotherapeutics, Inc.
0.5288
-7.08%
 
ADCT ADC Therapeutics SA
3.4200
-1.72%
 
LIFE aTyr Pharma, Inc.
1.9000
+2.70%
 
ENTX Entera Bio Ltd.
2.0000
-4.31%
 
FDMT 4D Molecular Therapeutics, Inc.
22.72
+0.66%